Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia

Luigi Gugliotta, Alessia Tieghi, Giovanni Tortorella, Potito Rosario Scalzulli, Rosanna Ciancia, Monia Lunghi, Emma Cacciola, Rossella Cacciola, Anna Candoni, Monica Crugnola, Katia Codeluppi, Emilio Usala, Giorgina Specchia, Vincenzo Martinelli, Fausto Palmieri, Ivana Pierri, Anna Marina Liberati, Alessandra Iurlo, Alberto Grossi, Alessandro M. VannucchiNicola Vianelli, Maria Gabriella Mazzucconi

Research output: Contribution to journalArticle

Abstract

This retrospective study of the thrombocythemia Italian registry (RIT) documented that 71 (30.6%) out of 232 ET patients experienced 88 cardiovascular adverse events (CV-AEs) during anagrelide treatment (522 pt-y). The rate of CV-AEs was: 24.1% for palpitations, 4.3% for angina, 3.5% for arterial hypertension, 3.0% for congestive heart failure, 1.8% for arrhythmia, 0.9% for AMI, 0.4% for pericardial effusion. CV-AEs led to treatment discontinuation in nine (3.9%) patients, while in the remaining cases they were managed by pharmacological intervention and/or patient life style improvement. CV-AEs had no relationship with patient characteristics (including older age). A significant relationship was found only with a higher anagrelide induction dose.In the absence of any agreed protocol, a cardiovascular instrumental evaluation (CV-IE) was performed in 102 (44%) patients before commencement of anagrelide (with higher rate after the anagrelide/Xagrid EMA approval of 2004), and in 84 (36%) patients during treatment. Patients with and without CV-IEs, who resulted completely balanced for all their characteristics, did not significantly differ in the occurrence of CV-AEs.In conclusion, this study on ET patients treated with anagrelide shows that CV-AEs, equally distributed in younger and older subjects, were mostly mild and easily manageable, allowing safe treatment continuation in the majority of cases. Moreover, routinely performing a CV-IE did not appear to anticipate the occurrence of CV-AEs.

Original languageEnglish
Pages (from-to)1557-1563
Number of pages7
JournalLeukemia Research
Volume35
Issue number12
DOIs
Publication statusPublished - Dec 2011

Fingerprint

Essential Thrombocythemia
Therapeutics
Thrombocytosis
Pericardial Effusion
anagrelide
Registries
Life Style
Cardiac Arrhythmias
Heart Failure
Retrospective Studies
Pharmacology
Hypertension

Keywords

  • Anagrelide
  • Cardiovascular adverse events
  • Echocardiogram
  • Essential thrombocythemia
  • Palpitation
  • Safety
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. / Gugliotta, Luigi; Tieghi, Alessia; Tortorella, Giovanni; Scalzulli, Potito Rosario; Ciancia, Rosanna; Lunghi, Monia; Cacciola, Emma; Cacciola, Rossella; Candoni, Anna; Crugnola, Monica; Codeluppi, Katia; Usala, Emilio; Specchia, Giorgina; Martinelli, Vincenzo; Palmieri, Fausto; Pierri, Ivana; Liberati, Anna Marina; Iurlo, Alessandra; Grossi, Alberto; Vannucchi, Alessandro M.; Vianelli, Nicola; Mazzucconi, Maria Gabriella.

In: Leukemia Research, Vol. 35, No. 12, 12.2011, p. 1557-1563.

Research output: Contribution to journalArticle

Gugliotta, L, Tieghi, A, Tortorella, G, Scalzulli, PR, Ciancia, R, Lunghi, M, Cacciola, E, Cacciola, R, Candoni, A, Crugnola, M, Codeluppi, K, Usala, E, Specchia, G, Martinelli, V, Palmieri, F, Pierri, I, Liberati, AM, Iurlo, A, Grossi, A, Vannucchi, AM, Vianelli, N & Mazzucconi, MG 2011, 'Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia', Leukemia Research, vol. 35, no. 12, pp. 1557-1563. https://doi.org/10.1016/j.leukres.2011.06.030
Gugliotta, Luigi ; Tieghi, Alessia ; Tortorella, Giovanni ; Scalzulli, Potito Rosario ; Ciancia, Rosanna ; Lunghi, Monia ; Cacciola, Emma ; Cacciola, Rossella ; Candoni, Anna ; Crugnola, Monica ; Codeluppi, Katia ; Usala, Emilio ; Specchia, Giorgina ; Martinelli, Vincenzo ; Palmieri, Fausto ; Pierri, Ivana ; Liberati, Anna Marina ; Iurlo, Alessandra ; Grossi, Alberto ; Vannucchi, Alessandro M. ; Vianelli, Nicola ; Mazzucconi, Maria Gabriella. / Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia. In: Leukemia Research. 2011 ; Vol. 35, No. 12. pp. 1557-1563.
@article{02a7c6220cf64b1ab3ce9d3f35a13229,
title = "Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia",
abstract = "This retrospective study of the thrombocythemia Italian registry (RIT) documented that 71 (30.6{\%}) out of 232 ET patients experienced 88 cardiovascular adverse events (CV-AEs) during anagrelide treatment (522 pt-y). The rate of CV-AEs was: 24.1{\%} for palpitations, 4.3{\%} for angina, 3.5{\%} for arterial hypertension, 3.0{\%} for congestive heart failure, 1.8{\%} for arrhythmia, 0.9{\%} for AMI, 0.4{\%} for pericardial effusion. CV-AEs led to treatment discontinuation in nine (3.9{\%}) patients, while in the remaining cases they were managed by pharmacological intervention and/or patient life style improvement. CV-AEs had no relationship with patient characteristics (including older age). A significant relationship was found only with a higher anagrelide induction dose.In the absence of any agreed protocol, a cardiovascular instrumental evaluation (CV-IE) was performed in 102 (44{\%}) patients before commencement of anagrelide (with higher rate after the anagrelide/Xagrid EMA approval of 2004), and in 84 (36{\%}) patients during treatment. Patients with and without CV-IEs, who resulted completely balanced for all their characteristics, did not significantly differ in the occurrence of CV-AEs.In conclusion, this study on ET patients treated with anagrelide shows that CV-AEs, equally distributed in younger and older subjects, were mostly mild and easily manageable, allowing safe treatment continuation in the majority of cases. Moreover, routinely performing a CV-IE did not appear to anticipate the occurrence of CV-AEs.",
keywords = "Anagrelide, Cardiovascular adverse events, Echocardiogram, Essential thrombocythemia, Palpitation, Safety, Toxicity",
author = "Luigi Gugliotta and Alessia Tieghi and Giovanni Tortorella and Scalzulli, {Potito Rosario} and Rosanna Ciancia and Monia Lunghi and Emma Cacciola and Rossella Cacciola and Anna Candoni and Monica Crugnola and Katia Codeluppi and Emilio Usala and Giorgina Specchia and Vincenzo Martinelli and Fausto Palmieri and Ivana Pierri and Liberati, {Anna Marina} and Alessandra Iurlo and Alberto Grossi and Vannucchi, {Alessandro M.} and Nicola Vianelli and Mazzucconi, {Maria Gabriella}",
year = "2011",
month = "12",
doi = "10.1016/j.leukres.2011.06.030",
language = "English",
volume = "35",
pages = "1557--1563",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Ltd",
number = "12",

}

TY - JOUR

T1 - Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia

AU - Gugliotta, Luigi

AU - Tieghi, Alessia

AU - Tortorella, Giovanni

AU - Scalzulli, Potito Rosario

AU - Ciancia, Rosanna

AU - Lunghi, Monia

AU - Cacciola, Emma

AU - Cacciola, Rossella

AU - Candoni, Anna

AU - Crugnola, Monica

AU - Codeluppi, Katia

AU - Usala, Emilio

AU - Specchia, Giorgina

AU - Martinelli, Vincenzo

AU - Palmieri, Fausto

AU - Pierri, Ivana

AU - Liberati, Anna Marina

AU - Iurlo, Alessandra

AU - Grossi, Alberto

AU - Vannucchi, Alessandro M.

AU - Vianelli, Nicola

AU - Mazzucconi, Maria Gabriella

PY - 2011/12

Y1 - 2011/12

N2 - This retrospective study of the thrombocythemia Italian registry (RIT) documented that 71 (30.6%) out of 232 ET patients experienced 88 cardiovascular adverse events (CV-AEs) during anagrelide treatment (522 pt-y). The rate of CV-AEs was: 24.1% for palpitations, 4.3% for angina, 3.5% for arterial hypertension, 3.0% for congestive heart failure, 1.8% for arrhythmia, 0.9% for AMI, 0.4% for pericardial effusion. CV-AEs led to treatment discontinuation in nine (3.9%) patients, while in the remaining cases they were managed by pharmacological intervention and/or patient life style improvement. CV-AEs had no relationship with patient characteristics (including older age). A significant relationship was found only with a higher anagrelide induction dose.In the absence of any agreed protocol, a cardiovascular instrumental evaluation (CV-IE) was performed in 102 (44%) patients before commencement of anagrelide (with higher rate after the anagrelide/Xagrid EMA approval of 2004), and in 84 (36%) patients during treatment. Patients with and without CV-IEs, who resulted completely balanced for all their characteristics, did not significantly differ in the occurrence of CV-AEs.In conclusion, this study on ET patients treated with anagrelide shows that CV-AEs, equally distributed in younger and older subjects, were mostly mild and easily manageable, allowing safe treatment continuation in the majority of cases. Moreover, routinely performing a CV-IE did not appear to anticipate the occurrence of CV-AEs.

AB - This retrospective study of the thrombocythemia Italian registry (RIT) documented that 71 (30.6%) out of 232 ET patients experienced 88 cardiovascular adverse events (CV-AEs) during anagrelide treatment (522 pt-y). The rate of CV-AEs was: 24.1% for palpitations, 4.3% for angina, 3.5% for arterial hypertension, 3.0% for congestive heart failure, 1.8% for arrhythmia, 0.9% for AMI, 0.4% for pericardial effusion. CV-AEs led to treatment discontinuation in nine (3.9%) patients, while in the remaining cases they were managed by pharmacological intervention and/or patient life style improvement. CV-AEs had no relationship with patient characteristics (including older age). A significant relationship was found only with a higher anagrelide induction dose.In the absence of any agreed protocol, a cardiovascular instrumental evaluation (CV-IE) was performed in 102 (44%) patients before commencement of anagrelide (with higher rate after the anagrelide/Xagrid EMA approval of 2004), and in 84 (36%) patients during treatment. Patients with and without CV-IEs, who resulted completely balanced for all their characteristics, did not significantly differ in the occurrence of CV-AEs.In conclusion, this study on ET patients treated with anagrelide shows that CV-AEs, equally distributed in younger and older subjects, were mostly mild and easily manageable, allowing safe treatment continuation in the majority of cases. Moreover, routinely performing a CV-IE did not appear to anticipate the occurrence of CV-AEs.

KW - Anagrelide

KW - Cardiovascular adverse events

KW - Echocardiogram

KW - Essential thrombocythemia

KW - Palpitation

KW - Safety

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=80055112112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055112112&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.06.030

DO - 10.1016/j.leukres.2011.06.030

M3 - Article

C2 - 21764130

AN - SCOPUS:80055112112

VL - 35

SP - 1557

EP - 1563

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 12

ER -